Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Tafasitamab will be administered intravenously at protocol defined timepoints.”In the company’s words, NCT07104565 on ClinicalTrials.gov
- Tested for
- Immune Thrombocytopenia
- Main trialPhase 2
- “This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.”In the company’s words, NCT07104565 on ClinicalTrials.gov
Other drugs for Immune Thrombocytopenia
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
- QL0911Qilu Pharmaceutical · Phase 3
Coming up1
- 23 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 23 Sep 2027 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026